Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
In idiopathic Parkinson's disease massive cell death occurs in the dopamine-containing substantia nigra. A link between the vulnerability of nigral neurons and the prominent pigmentation of the substantia nigra, though long suspected, has not been proved. This possibility is supported by evidence that N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its metabolite MPP+, the latter of which causes destruction of nigral neurons, bind to neuromelanin. We have directly tested this hypothesis by a quantitative analysis of neuromelanin-pigmented neurons in control and parkinsonian midbrains. The findings demonstrate first that the dopamine-containing cell groups of the normal human midbrain differ markedly from each other in the percentage of neuromelanin-pigmented neurons they contain. Second, the estimated cell loss in these cell groups in Parkinson's disease is directly correlated (r = 0.97, P = 0.0057) with the percentage of neuromelanin-pigmented neurons normally present in them. Third, within each cell group in the Parkinson's brains, there is greater relative sparing of non-pigmented than of neuromelanin-pigmented neurons. This evidence suggests a selective vulnerability of the neuromelanin-pigmented subpopulation of dopamine-containing mesencephalic neurons in Parkinson's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The nigra’s neuromelanin derives from dopamine and occurs in autolysosomes rather than melanosomes (226).”
From Chemiexcitation: Mammalian Photochemistry in the Dark† (2023) · cites this paper as [226]
In the citing paper
“The concept of such a substantial loss of EC neurons before AD symptoms occur may be analogous to the observation that very substantial neuronal losses are present in the substantia nigra before extrapyramidal symptoms become apparent in Parkinson's disease (Hirsch et al., 1988).”
From Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease (1996) · cites this paper as Hirsch et al., 1988
In the citing paper
“very substantial neuronal losses are present in the substantia nigra before extrapyramidal symptoms become apparent in Parkinson's disease (Hirsch et al., 1988).”
From Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease (1996) · cites this paper as Hirsch et al., 1988
Citations
Cites
Dahlstroem, A., & Fuxé, K. (1964) · PubMed · Cited by 5,133
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Recent developments in Parkinson's disease
Fahn, S., Elton, R., MARSDEN, C. D., Calne, D. B., & Goldstein, M. (1986) · Raven Press eBooks · Cited by 2,306
Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4546 · Cited by 2,149
STEELE, J. C. (1964) · Archives of Neurology · doi:10.1001/archneur.1964.00460160003001 · Cited by 1,924
Recent Developments in Parkinson's Disease
Hurtig, H. I. (1987) · Neurology · doi:10.1212/wnl.37.5.893 · Cited by 1,920
Emson, P., Heffher, R. R., & Pearson, J. (1984) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198409000-00010 · Cited by 1,648
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90006-4 · Cited by 1,376
Gerfen, C., Herkenham, M., & Thibault, J. (1987) · The Journal of Neuroscience · doi:10.1523/jneurosci.07-12-03915.1987 · Cited by 803
Hirsch, E. C., Graybiel, A. M., Duyckaerts, C., & Javoy-Agid, F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.16.5976 · Cited by 554
Self-citation
Research works printed but not linked: 6
- Escourolle, R., De Recondo, J. & Gray, F. in Monoamines Noyaux gris cenlraux et syndromes de Parkinson (eds de Ajuriaguerra, J. & Gauthier, G.) 173–229 (Geneva, 1970).
- Marsden, C. D. J. Neural Trans. Suppl. 19, 121–141 (1983).
- Dahlström, A. & Fuxe, K. Acta physiol. scand. 62, (Suppl. 232) 1–55 (1964).
- Graybiel, A. M. & Ragsdale, C. W. Jr in Chemical Neuroanalomy (ed. Emson, P. C.) 427–504 (Raven, New York, 1983).
- Graham, D. G. Molec. Pharmacol. 14, 633–643 (1978).
- Lindquist, N. G. Acta radiol. Suppl. 325, 1–92 (1973).
Cited by
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
“Also reminiscent of PD (Hirsch et al., 1988), doparotenone may freely enter all cells, this study suggested minergic neurons that contain neuromelanin are more that dopaminergic neurons are preferentially sensitive susceptible to MPTP-induced degeneration (Herrero et al., 1993).”
BackgroundNeurodegenerative diseases and oxidative stress
Barnham, K. J., Masters, C. L., & Bush, A. I. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1330 · Cited by 3,683
“In PD, these neuromelanin-containing cells are most likely to be los”
BackgroundAGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
“Neuromelanin has been implicated in the pathogenesis of PD (Hirsch et al., 1988), but non-pigmented regions can be equally affected (Marsden, 1983).”
Melanin pigmentation in mammalian skin and its hormonal regulation
Slominski, A., Tobin, D. J., Shibahara, S., & Wortsman, J. (2004) · Physiological Reviews · doi:10.1152/physrev.00044.2003 · Cited by 2,015
“Idiopathic Parkinson’s disease is associated with massive cell death in the dopamine-derived neuromelanin-pigmented tyrosinase-positive substantia nigra (281, 826).”
BackgroundThe hippocampal-VTA loop: controlling the entry of information into long-term memory
Lisman, J. E., & Grace, A. A. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.002 · Cited by 1,983
“However, there is c much less degeneration of the VTA, at least until late r stages of the disease (Hirsch et al., 1988), which may i account for why memory-related problems are not a s major factor in the early stages of the disease.”
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease
Gómez-Isla, T., Price, J. L., McKeel Jr., D. W., Morris, J. C., Growdon, J. H., & Hyman, B. T. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-14-04491.1996 · Cited by 1,796
“disease (Hirsch et al., 1988).”
BackgroundThe Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
“One of these hypotheses suggests that neuromelanin increases cellular vulnerability, purporting a correlation between the proportion of this pigment in different brain regions and neuronal loss [68, 69].”
BackgroundThe substantia nigra of the human brain
Damier, P., Hirsch, E. C., Agid, Y., & Graybiel, A. M. (1999) · Brain · doi:10.1093/brain/122.8.1437 · Cited by 1,756
“These observations confirm the earlier reports (Hirsch et al., 1988; Germanet al., 1989).”
BackgroundInfluentialSelf-citationNeurotransmitters and neuromodulators in the basal ganglia
Graybiel, A. M. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90104-i · Cited by 1,576
Self-citationMicroglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism
Block, M. L., & Hong, J.-S. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.06.004 · Cited by 1,557
“Analysis of the postmortem PD patient SN indicates that neuromelanin levels are significantly reduced, which is consistent with the loss of DA neurons (Hirsch et al., 1988; Zecca et al., 2002).”
ResultDisease duration and the integrity of the nigrostriatal system in Parkinson’s disease
Kordower, J. H., Olanow, C. W., Dodiya, H. B., Chu, Y., Beach, T. G., Adler, C. H., Halliday, G. M., & Bartus, R. T. (2013) · Brain · doi:10.1093/brain/awt192 · Cited by 1,286
Renal and neuronal abnormalities in mice lacking GDNF
Moore, M. W., Klein, R. D., Fariñas, I., Sauer, H., Armanini, M., Phillips, H., Reichardt, L. F., Ryan, A. M., Carver-Moore, K., & Rosenthal, A. (1996) · Nature · doi:10.1038/382076a0 · Cited by 1,271
Blum, D., Torch, S., Lambeng, N., Nissou, M.-F., Benabid, A.-L., Sadoul, R., & Verna, J.-M. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(01)00003-x · Cited by 1,246
Selective neuronal vulnerability to oxidative stress in the brain
Wang (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00012 · Cited by 1,008
“In Parkinson’s disease (PD), dopaminergic neurons of the substantia nigra are the primary neurons undergoing cell death (Hirsch et al., 1988; Damier et al., 1999; Dauer and Przedborski, 2003).”
Dopamine depletion impairs precursor cell proliferation in Parkinson disease
Höglinger, G. U., Rizk, P., Muriel, M. P., Duyckaerts, C., Oertel, W. H., Caille, I., & Hirsch, E. C. (2004) · Nature Neuroscience · doi:10.1038/nn1265 · Cited by 944
“dtd" [ ]> In Parkinson disease, dopaminergic midbrain neurons degenerate, leading to cerebral dopamine depletio”
The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
Fahn, S., & Cohen, G. (1992) · Annals of Neurology · doi:10.1002/ana.410320616 · Cited by 927
α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies
Wong, Y. C., & Krainc, D. (2017) · Nature Medicine · doi:10.1038/nm.4269 · Cited by 897
Matsuda, W., Furuta, T., Nakamura, K. C., Hioki, H., Fujiyama, F., Arai, R., & Kaneko, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4029-08.2009 · Cited by 865
“%) of neurons in the SNc occurs in most patients before parkinsonian symptoms appear (Hirsch et al., 1988).”
BackgroundTFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity
Decressac, M., Mattsson, B., Weikop, P., Lundblad, M., Jakobsson, J., & Björklund, A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305623110 · Cited by 753
“This finding provides support for the idea that the differential vulnerability of nigral and VTA neurons, which is a prominent feature also in human PD (49, 53), may be because of intrinsic differences in the efficiency of lysosomal clearance, and thus the ability of the neurons to resist against toxic concentrations…”
ResultHuman iPSC-based modeling of late-onset disease via progerin-induced aging
Miller, J. D., Ganat, Y. M., Kishinevsky, S., Bowman, R. L., Liu, B., Tu, E. Y., Mandal, P. K., Vera, E., Shim, J.-W., Kriks, S., et al. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.11.006 · Cited by 777
Saucedo-Cardenas, O., Quintana-Hau, J. D., Le, W.-D., Smidt, M. P., Cox, J. J., De Mayo, F., Burbach, J. P. H., & Conneely, O. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.4013 · Cited by 742
Hartmann, A., Hunot, S., Michel, P. P., Muriel, M.-P., Vyas, S., Faucheux, B. A., Mouatt-Prigent, A., Turmel, H., Srinivasan, A., Ruberg, M., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040556597 · Cited by 715
Self-citationPathoanatomy of Parkinson’s disease
Braak, H., & Braak, E. (2000) · Journal of Neurology · doi:10.1007/pl00007758 · Cited by 693
Pathology of Parkinson’s disease: Changes other than the nigrostriatal pathway
Jellinger, K. A. (1991) · Molecular and Chemical Neuropathology · doi:10.1007/bf03159935 · Cited by 684
Hunot, S., Brugg, B., Ricard, D., Michel, P. P., Muriel, M.-P., Ruberg, M., Faucheux, B. A., Agid, Y., & Hirsch, E. C. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7531 · Cited by 678
Self-citationInteractions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease
Zucca, F. A., Segura-Aguilar, J., Ferrari, E., Muñoz, P., Paris, I., Sulzer, D., Sarna, T., Casella, L., & Zecca, L. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.09.012 · Cited by 659
“Some studies suggested that neurons with the highest NM content are more susceptible to death, while other studies reported that lightly pigmented neurons are more vulnerable in PD (Gibb, 1992; Hirsch et al., 1988; Kastner et al., 1992; Mann and Yates, 1983; Pakkenberg et al., 1991).”
Neuroinflammation in Parkinson's disease
Hirsch, E. C., Vyas, S., & Hunot, S. (2012) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70065-7 · Cited by 657
“Parkinson’s disease (PD) is a neurodegenerative disorder characterized by a loss of dopaminergic neurons in the substantia nigra (SN) and the presence of a-synuclein deposits in various brain regions [1,2].”
BackgroundUnderstanding Dopaminergic Cell Death Pathways in Parkinson Disease
Michel, P. P., Hirsch, E. C., & Hunot, S. (2016) · Neuron · doi:10.1016/j.neuron.2016.03.038 · Cited by 600
Nitric oxide synthase and neuronal vulnerability in parkinson's disease
Hunot, S., Boissière, F., Faucheux, B., Brugg, B., Mouatt-Prigent, A., Agid, Y., & Hirsch, E. C. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00578-1 · Cited by 595
Self-citationDopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates
Berger, B., Gaspar, P., & Verney, C. (1991) · Trends in Neurosciences · doi:10.1016/0166-2236(91)90179-x · Cited by 588
Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease
Sulzer, D. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.009 · Cited by 587
“comparative sparing of the neighboring NM ventral tegmental area (VTA) DA neurons [56, 57 ].”
BackgroundChen, P.-C., Vargas, M. R., Pani, A. K., Smeyne, R. J., Johnson, D. A., Kan, Y. W., & Johnson, J. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813361106 · Cited by 579
“Dopaminergic neuron loss results in reduced striatal dopamine (DA) and the hallmark clinical features of PD (3).”
BackgroundThe substantia nigra of the human brain
Damier, P., Hirsch, E. C., Agid, Y., & Graybiel, A. M. (1999) · Brain · doi:10.1093/brain/122.8.1421 · Cited by 578
“For some authors, the medial lemniscus constitutes the dorsal border of the substantia nigra (Hirsch et al., 1988; Fearnley and Lees, 1991).”
BackgroundMethodResultInfluentialSelf-citationGibb, W. R., & Lees, A. J. (1991) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.54.5.388 · Cited by 574
The Synucleinopathies: Twenty Years On
Goedert, M., Jakes, R., & Spillantini, M. G. (2017) · Journal of Parkinson’s Disease · doi:10.3233/jpd-179005 · Cited by 569
“The differential vulnerability of nigral and ventral tegmental dopaminergic neurons, which has been documented in PD [184], may be due to differences in lysosomal clearance [182] and/or a higher basal rate of oxidative phosphorylation and a more complex axonal arborisation [185].”
BackgroundRole of oxidation in the neurotoxic effects of intrastriatal dopamine injections.
Hastings, T. G., Lewis, D. A., & Zigmond, M. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.5.1956 · Cited by 547
Advances in Our Understanding of the Mechanisms of the Neurotoxicity of MPTP and Related Compounds
Tipton, K. F., & Singer, T. P. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb13610.x · Cited by 539
Hirsch, E. C., Brandel, J. ‐., Galle, P., Javoy‐Agid, F., & Agid, Y. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb08170.x · Cited by 537
Self-citationMosharov, E. V., Larsen, K. E., Kanter, E., Phillips, K. A., Wilson, K., Schmitz, Y., Krantz, D. E., Kobayashi, K., Edwards, R. H., & Sulzer, D. (2009) · Neuron · doi:10.1016/j.neuron.2009.01.033 · Cited by 534
“Conversely, dopaminergic neurons in the VTA, which are spared in PD, produce minimal neuromelanin over a lifetime (Hirsch et al., 1988; Liang et al., 2004; Zecca et al., 2001).”
Parkinson's disease: pathophysiology
Agid, Y. (1991) · The Lancet · doi:10.1016/0140-6736(91)92989-f · Cited by 530
Self-citationSelective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains
Sofic, E., Paulus, W., Jellinger, K., Riederer, P., & Youdim, M. B. H. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb02017.x · Cited by 524
Protective and toxic roles of dopamine in Parkinson's disease
Segura‐Aguilar, J., Paris, I., Muñoz, P., Ferrari, E., Zecca, L., & Zucca, F. A. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12686 · Cited by 498
“Indeed, Parkinson’s disease is characterized by preferential loss of those dopaminergic neurons that contain NM (Marsden 1983; Hirsch et al. 1988; Gibb and Lees 1991; Kastner et al. 1992).”
BackgroundOxidative stress and human health
Rahman, T., Hosen, I., Islam, M. M. T., & Shekhar, H. U. (2012) · Advances in Bioscience and Biotechnology · doi:10.4236/abb.2012.327123 · Cited by 489
“In PD, these neuromelanin-containing cells are most likely to be lost [44].”
BackgroundMelanins and melanogenesis: from pigment cells to human health and technological applications
d'Ischia, M., Wakamatsu, K., Cicoira, F., Di Mauro, E., Garcia‐Borron, J. C., Commo, S., Galván, I., Ghanem, G., Kenzo, K., Meredith, P., et al. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12393 · Cited by 490
“In PD, a preferential loss of SN dopamine neurons containing NM occurs with respect to non-pigmented neurons, and it has been long discussed if NM can increase neuronal vulnerability in PD (Hirsch et al., 1988; Hornykiewicz and Kish, 1987; Marsden, 1983).”
BackgroundBezard, E., Dovero, S., Prunier, C., Ravenscroft, P., Chalon, S., Guilloteau, D., Crossman, A. R., Bioulac, B., Brotchie, J. M., & Gross, C. E. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-17-06853.2001 · Cited by 483
“They identified compartmental subdivisions within the SNc (Damier et al., 1999a), each of them being differentially affected by progression of the disease (Hirsch et al., 1988; Damier et al., 1999b).”
BackgroundBasal Ganglia Disorders Associated with Imbalances in the Striatal Striosome and Matrix Compartments
Crittenden, J. R., & Graybiel, A. M. (2011) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2011.00059 · Cited by 481
“…reported increased vulnerability of neurons located in the ventro-lateral SNc that are calbindin-D28k-negative (Yamada et al., 1990), but this pattern is not uniform across studies and is likely dependent on the individual and how the SNc subregions are defined (Hirsch et al., 1988; Gibb, 1992).”
BackgroundSelf-citationInduction of midbrain dopaminergic neurons by Sonic hedgehog
Hynes, M., Porter, J. A., Chiang, C., Chang, D., Tessier-Lavigne, M., Beachy, P. A., & Rosenthal, A. (1995) · Neuron · doi:10.1016/0896-6273(95)90062-4 · Cited by 482
Oxidative stress: Free radical production in neural degeneration
Götz, M. E., Künig, G., Riederer, P., & Youdim, M. B. H. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90055-8 · Cited by 482
Signaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions
Dong-Chen, X., Yong, C., Yang, X., Chen-Yu, S., & Li-Hua, P. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01353-3 · Cited by 469
“Lewy bodies multiply as Parkinson’s disease advances, impacting non-dopaminergic neurons in other brain regions in addition to the limbic and neocortical regions.(26,27) Finally, neurons outside of the central nervous system (CNS), such those in the olfactory bulb or mesenteric system, deteriorate as a result of PD.”
BackgroundGlutathione peroxidase, glial cells and Parkinson's disease
Damier, P., Hirsch, E. C., Zhang, P., Agid, Y., & Javoy-Agid, F. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90175-f · Cited by 466
Self-citationTrottier, Y., Devys, D., Imbert, G., Saudou, F., An, I., Lutz, Y., Weber, C., Agid, Y., Hirsch, E. C., & Mandel, J.-L. (1995) · Nature Genetics · doi:10.1038/ng0595-104 · Cited by 452
Self-citationOxidative Stress in Parkinson's Disease: A Mechanism of Pathogenic and Therapeutic Significance
Zhou, C., Huang, Y., & Przedborski, S. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.023 · Cited by 450
The Role of Glial Reaction and Inflammation in Parkinson's Disease
HIRSCH, E. C., BREIDERT, T., ROUSSELET, E., HUNOT, S., HARTMANN, A., & MICHEL, P. P. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07478.x · Cited by 449
Living on the edge with too many mouths to feed: Why dopamine neurons die
Bolam, J. P., & Pissadaki, E. K. (2012) · Movement Disorders · doi:10.1002/mds.25135 · Cited by 436
“DOI: 10.1002/mds.25135 1478 Movement Disorders, Vol. 27, No. 12, 2012 (MPPþ), both of which are used to create animal models of PD.17 Their selectivity for DA neurons is because their access to the intracellular compartment is dependent on the DA transporter, which is only expressed by DA neurons and, interestingly, a…”
BackgroundInfluentialParkinson’s disease dementia: a neural networks perspective
Gratwicke, J., Jahanshahi, M., & Foltynie, T. (2015) · Brain · doi:10.1093/brain/awv104 · Cited by 435
“However, in stark contrast to the nigrostriatal pathology underlying the motor aspects of the disorder (Fahn et al. , 1971; Hirsch et al. , 1988), the pathophysiological mechanisms underlying PDD remain obscure, which hinders the development of new therapies.”
Pennica, D., Shaw, K. J., Swanson, T. A., Moore, M. W., Shelton, D. L., Zioncheck, K. A., Rosenthal, A., Taga, T., Paoni, N. F., & Wood, W. I. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.18.10915 · Cited by 429
Oxidative stress and regulated cell death in Parkinson’s disease
Dionísio, P. A., Amaral, J. D., & Rodrigues, C. M. P. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101263 · Cited by 424
On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease
Giguère, N., Burke Nanni, S., & Trudeau, L.-E. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00455 · Cited by 413
Salazar, J., Mena, N., Hunot, S., Prigent, A., Alvarez-Fischer, D., Arredondo, M., Duyckaerts, C., Sazdovitch, V., Zhao, L., Garrick, L. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804373105 · Cited by 409
“This finding is relevant in view of the known preferential vulnerability of SNpc DNs in PD compared with VTA neurons (27).”
ResultNeuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease
Halliday, G. M., Li, Y. W., Blumbergs, P. C., Joh, T. H., Cotton, R. G. H., Howe, P. R. C., Blessing, W. W., & Geffen, L. B. (1990) · Annals of Neurology · doi:10.1002/ana.410270405 · Cited by 408
Midbrain dopaminergic cell loss in parkinson's disease: Computer visualization
German, D. C., Manaye, K., Smith, W. K., Woodward, D. J., & Saper, C. B. (1989) · Annals of Neurology · doi:10.1002/ana.410260403 · Cited by 396
Nurr1 Is Required for Maintenance of Maturing and Adult Midbrain Dopamine Neurons
Kadkhodaei, B., Ito, T., Joodmardi, E., Mattsson, B., Rouillard, C., Carta, M., Muramatsu, S.-I., Sumi-Ichinose, C., Nomura, T., Metzger, D., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3910-09.2009 · Cited by 382
“How may dysregulated Nurr1 activity contribute to PD? Studies in PD patients have shown that, in early stages of the disease, SNc cell bodies are relatively spared compared with the loss of DA in the putamen (Fearnley and Lees, 1991) and that a significant fraction of the surviving, pigmented, DA somata in the SNc hav…”
BackgroundLeenders, K. L., Salmon, E. P., Tyrrell, P., Perani, D., Brooks, D. J., Sager, H., Jones, T., Marsden, C. D., & Frackowiak, R. S. J. (1990) · Archives of Neurology · doi:10.1001/archneur.1990.00530120034007 · Cited by 376
Breidert, T., Callebert, J., Heneka, M. T., Landreth, G., Launay, J. M., & Hirsch, E. C. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00990.x · Cited by 373
“Immunohistochemistry was performed as described previously (Hirsch et al. 1988) on free-floating cryomicrotome-cut sections (20 lm in thickness) encompassing the entire striatum and midbrain.”
MethodBrain iron pathways and their relevance to Parkinson's disease
Berg, D., Gerlach, M., Youdim, M. B. H., Double, K. L., Zecca, L., Riederer, P., & Becker, G. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00608.x · Cited by 362
“Melanized neurons are also the main target of pathogenetic mechanisms in PD (Hirsch et al. 1988).”
BackgroundLoss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease
Halliday, G. M., Blumbergs, P. C., Cotton, R. G. H., Blessing, W. W., & Geffen, L. B. (1990) · Brain Research · doi:10.1016/0006-8993(90)90733-r · Cited by 366
GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo
Arenas, E., Trupp, M., Åkerud, P., & Ibáñez, C. F. (1995) · Neuron · doi:10.1016/0896-6273(95)90024-1 · Cited by 363
Chung, C. Y., Seo, H., Sonntag, K. C., Brooks, A., Lin, L., & Isacson, O. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi178 · Cited by 361
FEDOROW, H., TRIBL, F., HALLIDAY, G., GERLACH, M., RIEDERER, P., & DOUBLE, K. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.02.001 · Cited by 350
Pissadaki, E. K., & Bolam, J. P. (2013) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2013.00013 · Cited by 348
“ORIGINAL RESEARCH ARTICLE published: 18 March 2013 doi: 10.3389/fncom.2013.00013 The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in”
BackgroundInfluentialJellinger, K. A. (1999) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-6360-3_1 · Cited by 347
The two-century journey of Parkinson disease research
Przedborski, S. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.25 · Cited by 345
The Relevance of Iron in the Pathogenesis of Parkinson's Disease
GÖTZ, M. E., DOUBLE, K., GERLACH, M., YOUDIM, M. B. H., & RIEDERERE, P. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.017 · Cited by 342
Carballo-Carbajal, I., Laguna, A., Romero-Giménez, J., Cuadros, T., Bové, J., Martinez-Vicente, M., Parent, A., Gonzalez-Sepulveda, M., Peñuelas, N., Torra, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08858-y · Cited by 316
Toxicity of 6‐hydroxydopamine and dopamine for dopaminergic neurons in culture
Michel, P. P., & Hefti, F. (1990) · Journal of Neuroscience Research · doi:10.1002/jnr.490260405 · Cited by 338
Ferroptosis and cell death mechanisms in Parkinson's disease
Guiney, S. J., Adlard, P. A., Bush, A. I., Finkelstein, D. I., & Ayton, S. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.01.004 · Cited by 338
“loss (Hirsch et al., 1988) was recently cast into doubt when an extensive post-mortem study indicated that there was no clear”
Oxidative stress and antioxidant therapy in Parkinson's disease
Ebadi, M., Srinivasan, S. K., & Baxi, M. D. (1996) · Progress in Neurobiology · doi:10.1016/0301-0082(95)00029-1 · Cited by 336
Pattern of brain destruction in Parkinson's and Alzheimer's diseases
Braak, H., Braak, E., Yilmazer, D., de Vos, R. A. I., Jansen, E. N. H., & Bohl, J. (1996) · Journal of Neural Transmission · doi:10.1007/bf01276421 · Cited by 329
“Many dopaminergic neurons of the substantia nigra, the mesencephalic central gray, and the hypothalamus consistently escape destruction (Matzuk and Saper, 1985; Hirsch et al., 1988; Agid et al., 1993), while numerous non-dopaminergic neuronal types display severe changes.”
BackgroundPterin-Dependent Amino Acid Hydroxylases
Kappock, T. J., & Caradonna, J. P. (1996) · Chemical Reviews · doi:10.1021/cr9402034 · Cited by 326
Thiruchelvam, M., Brockel, B. J., Richfield, E. K., Baggs, R. B., & Cory-Slechta, D. A. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02496-3 · Cited by 324
Neuronal vulnerability, pathogenesis, and Parkinson's disease
Sulzer, D., & Surmeier, D. J. (2013) · Movement Disorders · doi:10.1002/mds.25095 · Cited by 315
“Although most obvious in the SNc and LC, NM is found in other central catecholamine neurons(37) and by more sensitive chemical methods in additional noncatecholaminergic neurons.(38,39) NM autophagic organelles are essentially identical to lipofuscin (LF) organelles, a different pigment derived from oxidized lipids an…”
Huisman, E., Uylings, H. B. M., & Hoogland, P. V. (2004) · Movement Disorders · doi:10.1002/mds.10713 · Cited by 313
Dopamine, Immunity, and Disease
Channer, B., Matt, S. M., Nickoloff-Bybel, E. A., Pappa, V., Agarwal, Y., Wickman, J., & Gaskill, P. J. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000618 · Cited by 308
Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis
Jellinger, K., Kienzl, E., Rumpelmair, G., Riederer, P., Stachelberger, H., Ben‐Shachar, D., & Youdim, M. B. H. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb08362.x · Cited by 313
Dopamine Induces Apoptosis through an Oxidation-involved SAPK/JNK Activation Pathway
Luo, Y., Umegaki, H., Wang, X., Abe, R., & Roth, G. S. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.6.3756 · Cited by 310
Hall, H., Reyes, S., Landeck, N., Bye, C., Leanza, G., Double, K., Thompson, L., Halliday, G., & Kirik, D. (2014) · Brain · doi:10.1093/brain/awu193 · Cited by 302
“…in the substantia nigra and subsequent reduction in striatal dopamine levels are responsible for the development of motor symptoms in Parkinson’s disease (Fahn et al., 1971; Hirsch et al., 1988), the exact pathophysiology underlying the development of dementia in Parkinson’s disease is less clear.”
BackgroundParain, K., Murer, M. G., Yan, Q., Faucheux, B., Agid, Y., Hirsch, E., & Raisman-Vozari, R. (1999) · NeuroReport · doi:10.1097/00001756-199902250-00021 · Cited by 303
Self-citationKinetic and Structural Analysis of the Early Oxidation Products of Dopamine
Bisaglia, M., Mammi, S., & Bubacco, L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610893200 · Cited by 303
The possible role of iron in the etiopathology of parkinson's disease
Youdim, M. B. H., Ben‐Shachar, D., & Riederer, P. (1993) · Movement Disorders · doi:10.1002/mds.870080102 · Cited by 301
“pars compacta, where iron is increased (9), degenerate selectively (20).”
Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking
Choi, B.-K., Choi, M.-G., Kim, J.-Y., Yang, Y., Lai, Y., Kweon, D.-H., Lee, N. K., & Shin, Y.-K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218424110 · Cited by 300
“It should be noted that A9 dopaminergic neurons, which contain a high level of α-Syn (48, 49) and increased pigmentation by neuromelanin in the early stage of PD before producing Lewy bodies (12, 50, 51), exhibit early vulnerability.”
BackgroundBen‐Shachar, D., Eshel, G., Finberg, J. P. M., & Youdim, M. B. H. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb11444.x · Cited by 299
Testa, C. M., Sherer, T. B., & Greenamyre, J. T. (2005) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.11.007 · Cited by 299
THE ROLE OF VESICULAR TRANSPORT PROTEINS IN SYNAPTIC TRANSMISSION AND NEURAL DEGENERATION
Liu, Y., & Edwards, R. H. (1997) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.20.1.125 · Cited by 296
Neuroinflammatory processes in Parkinson's disease
Hirsch, E. C., Hunot, S., & Hartmann, A. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.10.013 · Cited by 296
“[3] Hirsch EC, Graybiel AM, Agid Y.”
BackgroundSeroogy, K. B., Lundgren, K. H., Tran, T. M. D., Guthrie, K. M., Isackson, P. J., & Gall, C. M. (1994) · Journal of Comparative Neurology · doi:10.1002/cne.903420302 · Cited by 294
Youdim, M. B. H., Ben-Shachar, D., & Riederer, P. (1989) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1989.tb01782.x · Cited by 292
Iron‐Melanin Interaction and Lipid Peroxidation: Implications for Parkinson's Disease
Ben‐Shachar, D., Riederer, P., & Youdim, M. B. H. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb06358.x · Cited by 287
“The increase of iron in parkinsonian SN and the susceptibility of the melaninized SN dopamine neurons to degeneration in Parkinson’s disease (Hirsch et al., 1988) indicate that iron-melanin interaction could be crucial in the initiation of neurodegeneration resulting from oxidative stress.”
BackgroundStriatal dopamine deficiency in parkinson's disease: Role of aging
Scherman, D., Desnos, C., Darchen, F., Pollak, P., Javoy‐Agid, F., & Agid, Y. (1989) · Annals of Neurology · doi:10.1002/ana.410260409 · Cited by 286
Self-citationCuO nanoparticle sensor for the electrochemical determination of dopamine
Reddy, S., Kumara Swamy, B. E., & Jayadevappa, H. (2012) · Electrochimica Acta · doi:10.1016/j.electacta.2011.11.091 · Cited by 284
Metadata
- Authors
- Hirsch, E., Graybiel, A. M., & Agid, Y. A.
- Affiliations
- Massachusetts Institute of Technology (US)
- Inserm (FR)
- ORCID
- Graybiel, Ann M.
- Venue
- Nature
- Published
- 1988-07
- Volume
- 334
- Issue
- 6180
- Pages
- 345-348
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2054421268
- Semantic Scholar
- a3233ab8e74d927c8cdec03d6fc967cde7332aaf
- Cited by
- 1,301
- References
- 20
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 29 · 2023: 35 · 2022: 47 · 2021: 51 · 2020: 48 · 2019: 45 · 2018: 37 · 2017: 34 · 2016: 48 · 2015: 49 · 2014: 47 · 2013: 43 · 2012: 50
- FWCI
- 23.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, neuromelanin, dopaminergic neurons, substantia nigra, neuronal vulnerability, MPTP, MPP+, selective neuronal degeneration, midbrain, cell loss
- MeSH terms
- Acetylcholinesterase, Dopamine, Humans, Melanins, Nerve Degeneration, Neurons, Parkinson Disease, Pyridines, Pyridinium Compounds, Tyrosine 3-Monooxygenase, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 1-Methyl-4-phenylpyridinium
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.